checkAd
    Xeris Biopharma Holdings
    Aktie
    ISIN: US98422E1038 WKN: A3C4ZC SYM: 2B30 Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    2,0140
     
    EUR
    -1,76 %
    -0,0360 EUR
    Letzter Kurs 12:55:36 Tradegate
    Geldkurs
    16:30:58
    1,9860
     
    EUR
    2.400 STK
    Briefkurs
    16:30:58
    2,0540
     
    EUR
    2.000 STK

    Xeris Biopharma Holdings Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushing’s Syndrome Patients at ENDO 2024
    03.06.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Xeris to Participate in the Jefferies Global Healthcare Conference
    30.05.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
    09.05.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
    06.05.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
    02.05.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    03.04.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
    06.03.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
    06.03.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 04.03.2024
    04.03.24 · wO Chartvergleich · Myriad Genetics
    Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
    28.02.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
    05.02.24 · Business Wire (engl.) · Xeris Biopharma Holdings
    Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject Formulation of Teprotumumab
    10.01.24 · Business Wire (engl.) · Xeris Biopharma Holdings